Sun Pharma reported robust global specialty growth and resilient domestic sales in Q3, despite US generics headwinds. Recent product launches and pipeline advancements, including Unloxcyt and Leqselvi, are poised to drive long-term growth. Analysts maintain a ‘BUY’ rating, anticipating an 11-18% upside.
